CGEM - CIK 0001789972
Cullinan Therapeutics, Inc. trades as CGEM and has a market capitalization of $1.00 B, making it the #2637 largest US-listed company by market value. In its fiscal 2022 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$219.88M. This page tracks Cullinan Therapeutics, Inc. through 435 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Insider trade | 4 | 2026-05-06 |
| Insider sale notice | 144 | 2026-05-05 |
| S-3ASR | - | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
The largest companies sharing Cullinan Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Cullinan Therapeutics, Inc. (CGEM) has a market capitalization of $1.00 B as of 2026-05-29, ranking #2637 among US-listed companies.
Cullinan Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2022, a decrease of 100.0% year over year.
In its latest fiscal year Cullinan Therapeutics, Inc. reported a net loss of $219.88M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.